Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

HbA1c control, 9/13

Streck’s A1c-Cellular Linearity, an HbA1c linearity/calibration verification material with intact red blood cells, is now assayed for Roche Diagnostics’ Cobas c 311. It is a five-level assayed linearity material used to assess instrument accuracy and verify the patient reportable range of the HbA1c parameter. The product does not require reconstitution, which reduces the potential for human errors and saves time. The linearity material tests the entire reportable range of the instrument system, including the lyse step. Instrument-specific target values and

App for preventing preanalytical errors in blood gas testing, 9/13

Radiometer America offers its “Avoid Errors” application for the iPhone. The app allows users to identify typical preanalytical errors in blood gas testing. The content of the “Avoid Errors” application is threefold, with tips on how to prevent errors, a troubleshooting section, and a skill test. A handbook section in the app contains videos that show how to properly collect a blood gas sample by arterial puncture, through an arterial line, or by capillary sampling. The handbook also describes several

Immunoanalyzer licensed for clinical use in Canada, 10/13

Wako Diagnostics was issued three class III medical device licenses by Health Canada to market the uTAS-Wako i30 instrument with the serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) for clinical use in Canada. The AFP-L3 and DCP tests are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma.

Benchtop lead analyzer, 10/13

Magellan Diagnostics has received FDA 510(k) clearance to market its LeadCare Ultra benchtop blood lead testing system in the United States.

Wipes minimize cross-contamination, 10/13

Current Technologies’ Bio-Hazard wipes protect patients and employees from cross-contamination when opening and handling specimen containers and sputum cups. The white side of the Bio-Hazard wipe absorbs specimen contents and sputum, while the orange plastic backing prevents splash or leakage from containers to gloves.

New molecular test for Trichomonas vaginalis, 10/13

BD Diagnostics announced FDA clearance of its BD ProbeTec Trichomonas vaginalis Qx amplified DNA assay for the direct qualitative detection of T. vaginalis DNA in endocervical samples, vaginal samples, and neat urine specimens. This assay, developed to aid in the diagnosis of trichomoniasis, has been CE marked to the in vitro diagnostic directive.

SeraCare acquires KPL, 10/13

SeraCare Life Sciences has acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets.

Collaboration expands access to peanut allergy tests, 10/13

Thermo Fisher Scientific’s ImmunoCAP peanut component tests are now available through Quest Diagnostics. Unlike skin scratch testing, the ImmunoCAP peanut component tests measure a patient’s IgE sensitization to five individual peanut proteins, or allergen components.

MARKETPLACE

TRENDING